SUBCONJUCTIVAL IMPLANT FOR POSTERIOR SEGMENT DRUG DELIVERY
    5.
    发明申请
    SUBCONJUCTIVAL IMPLANT FOR POSTERIOR SEGMENT DRUG DELIVERY 审中-公开
    用于分支部门药物递送的分支植入物

    公开(公告)号:US20130274692A1

    公开(公告)日:2013-10-17

    申请号:US13814470

    申请日:2011-08-04

    IPC分类号: A61F9/00

    摘要: A therapeutic device can be configured to place the reservoir substantially between the conjunctiva and the scleral such that the size of the reservoir can be increased and the size of the scleral penetration decreased so as to decrease invasiveness. The device may comprise a substantially constant reservoir volume and drug release mechanism, in which the volume of the reservoir and mechanism are tuned to receive a quantity of therapeutic agent with a volume of injected formulation and release the therapeutic agent for an extended time with a release rate profile. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent, and a plurality of interconnecting channels can extend from the first side to the second side.

    摘要翻译: 治疗装置可以被配置为将储存器基本上放置在结膜和巩膜之间,使得储存器的尺寸可以增加并且巩膜穿透的尺寸减小以降低侵入性。 该装置可以包括基本上恒定的储存器体积和药物释放机构,其中储存器和机构的体积被调谐以接收一定量的具有注射制剂体积的治疗剂,并释放治疗剂延长的时间 费率简介。 多孔结构可以包括联接到储存器的第一侧和耦合到患者以释放治疗剂的第二侧,并且多个互连通道可以从第一侧延伸到第二侧。

    THERAPEUTIC AGENT FORMULATIONS FOR IMPLANTED DEVICES
    8.
    发明申请
    THERAPEUTIC AGENT FORMULATIONS FOR IMPLANTED DEVICES 审中-公开
    用于植入装置的治疗剂制剂

    公开(公告)号:US20140031769A1

    公开(公告)日:2014-01-30

    申请号:US13988298

    申请日:2011-11-18

    IPC分类号: A61F9/00

    摘要: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.

    摘要翻译: 治疗剂的可注射制剂可以包含治疗剂和稳定剂,使得当治疗剂从治疗装置释放时,大部分稳定剂保留在治疗装置中以稳定治疗剂。 可注射制剂可以包含一种或多种粘合剂颗粒或可侵蚀材料颗粒,使得可以将制剂注射到治疗装置中。 结合剂颗粒可以可逆地结合治疗剂以调节治疗剂的释放,并且可侵蚀的材料颗粒可以产生酸的质子,以增加治疗剂的稳定性并且可以调节治疗剂的释放。 治疗剂可以与稳定剂,结合剂颗粒或可侵蚀颗粒中的一种或多种组合以增加治疗剂的稳定性并且可以调节释放。